Drug Profile
Favezelimab/pembrolizumab - Merck Sharp & Dohme
Alternative Names: Coformulation favezelimab/pembrolizumab - Merck Sharp & Dohme; Mavezelimab/pembrolizumab - Merck Sharp & Dohme; MK 4280A; MK-4820A; Pembrolizumab/favezelimab - Merck Sharp & DohmeLatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Colorectal cancer; Haematological malignancies; Hodgkin's disease
- Phase II Endometrial cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer
- Phase I/II Bladder cancer; Malignant melanoma; Oesophageal cancer
- No development reported Solid tumours
Most Recent Events
- 15 Mar 2024 Merck Sharp & Dohme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Spain, Poland, South Korea, Israel, Germany, China, Canada, USA (IV) (NCT02720068)
- 29 Sep 2023 Phase-II clinical trials in Endometrial cancer (First-line therapy, Metastatic disease, Late-stage disease, Recurrent, Combination therapy) in Taiwan, Australia (IV) (NCT06036836)
- 29 Sep 2023 Phase-II clinical trials in Endometrial cancer (First-line therapy, Monotherapy, Metastatic disease, Late-stage disease, Recurrent) in Australia, Taiwan (IV) (NCT06036836)